Results 101 to 110 of about 1,181,836 (211)
Hierarchical Structured TiO2/Boron‐Doped Diamond for Efficient Photo‐Electrocatalytic Degradation
Rare Metals, Volume 45, Issue 5, May 2026.ABSTRACT
The discharge of refractory organic dye wastewater poses a significant threat to the ecological environment, necessitating the development of efficient treatment technologies. Herein, a uniform TiO2 array (TiO2‐AR) electrode is fabricated using a combination of magnetron sputtering and a mask plate process with a boron‐doped diamond (BDD ...Haiming Sun, Peng Li, Xia Zhang, Yuxiao Liu, Jinfei Zhao, Muhammad Humayun, Binghui Yang, Baochun Wang, Xuan Fang, Jiean Liao, Chundong Wang +10 morewiley +1 more sourcePrediction of short- and medium-term efficacy of biosimilar infliximab therapy. Do trough levels/antidrug antibody levels or clinical/biochemical markers play a more important role? [PDF]
, 2018 KBene, László, Bor, Renáta, Bíró, Edina, Farkas, Klaudia, Gasztonyi, Beáta, Gecse, Krisztina B., Golovics, Petra Anna, Gönczi, Lóránt, Kristóf, Tünde, Kürti, Zsuzsanna, Lakatos, László, Lakatos, Péter László, Lovász, Barbara Dorottya, Miheller, Pál, Molnár, Tamás, Palatka, Károly, Papp, Mária, Patai, Árpád, Rutka, Mariann, Salamon, Ágnes, Szamosi, Tamás, Szepes, Zoltán, Tóth, Gábor Tamás, Vincze, Áron, Végh, Zsuzsanna +24 morecore A new venue of TNF targeting [PDF]
, 2018 The first Food and Drug Administration-(FDA)-approved drugs were small, chemically-manufactured and highly active molecules with possible off-target effects, followed by protein-based medicines such as antibodies.Libert, Claude, Steeland, Sophie, Vandenbroucke, Roosmarijn +2 morecore +1 more sourceHost–Parasite Interaction Networks of Helminths of Sigmodontine Rodents in Two Different Areas of the Brazilian Atlantic Forest
Ecological Research, Volume 41, Issue 3, May 2026.Two helminth‐rodent networks were analyzed for two distinct areas. Network modularity, nestedness, and degree of specialization were calculated for each network. Higher network modularity than nestedness and high network specialization were observed in both networks, suggesting functional and/or taxonomic specialization between helminth species and ...Thiago dos Santos Cardoso, Natália Alves Costa, Socrates Fraga da Costa‐Neto, Gabriel Alves dos Santos Attanazio, Martín Roberto del Valle Alvarez, Arnaldo Maldonado Junior, Cecilia Siliansky de Andreazzi, Rosana Gentile +7 morewiley +1 more sourceExploring the histopathological signature of repeat‐mediated Fuchs endothelial corneal dystrophy
Acta Ophthalmologica, Volume 104, Issue 3, Page 333-341, May 2026.Abstract Purpose
To determine the histological differences between Fuchs endothelial corneal dystrophy (FECD) cases with and without the most common genetic risk factor, expansion of a CTG repeat (CTG18.1) within the TCF4 gene. Methods
Formalin‐fixed paraffin‐embedded corneal tissues were compared retrospectively, and CTG18.1 status was determined from Anne‐Marie S. Kladny, Nihar Bhattacharyya, Marcos Abreu Costa, Stephen J. Tuft, Caroline Thaung, Alice E. Davidson +5 morewiley +1 more sourceCertolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs : a systematic review and economic evaluation [PDF]
, 2017 BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (Adams, Adams, Ali, Anon, Antoni, Antoni, Antoni, Arthritis Foundation, Asaria, Askling, Atteno, Bansback, Baranauskaite, Bird, Bojke, Bowcock, Briggs, Brodszky, Capogrosso-Sansone, Carmona, Cawson, Centre for Reviews and Dissemination, Chang, Chen, Coates, Codreanu, Corbett, Corbett, Corbett, Craig, Cummins, Curtis, Department of Health (DH), Dias, Dias, Dias, Dixon, Dolan, Drummond, Eder, Einarson, Emery, European Medicines Agency, Fagerli, Fagerli, Fagerli, Felson, Galadari, Genovese, Girolomoni, Gladman, Gladman, Gladman, Glintborg, Glintborg, Glintborg, Gossec, Gottlieb, Gottlieb, Gottlieb, Gottlieb, GRAPPA, Gratacós, Haberhauer, Hartman, Helliwell, HM Treasury, Husted, Iannone, Joint Formulary Committee, Joint Formulary Committee, Julious, Kane, Karlsson, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kavanaugh, Kobelt, Kristensen, Krueger, Kyle, Langley, Lefebvre, Lefebvre, Leung, Leung, Madan, Maneiro, Mariette, McInnes, McInnes, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Mease, Michelsen, Migliore, Moll, Morgan, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence, National Institute for Health and Care Excellence (NICE), National Institute for Health and Care Excellence (NICE), Novartis Pharmaceuticals, Novartis Pharmaceuticals, Novartis Pharmaceuticals, Office for National Statistics, O’Connor, Picchianti-Diamanti, Poole, Poyner, Ramiro, Reveille, Ritchlin, Ritchlin, Rodgers, Ruderman, Saad, Saad, Salisbury NHS Foundation Trust, Schett, Shiel, Simard, Singh, Smith, Spiegelhalter, Sterry, Stolfa, Tarp, Taylor, Thaçi, Torii, Torre Alonso, Tzanetakos, Ungprasert, Wang, Wong, Wong, Yang, Yang, Yang, Zisman +157 morecore +2 more sourcesP902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study
Journal of Crohn's & Colitis
CT-P13 subcutaneous (SC) infliximab formulation showed superiority over placebo as maintenance therapy at Week 54 in Crohn’s disease (CD)1 and ulcerative colitis2.J. Colombel, S. Hanauer, W. Sandborn, B. Sands, S. Schreiber, S. Danese, J. Kierkus, R. Kulynych, M. Kłopocka, A. Lahat, M. Gonciarz, M. Osipenko, V. Borzan, M. Kowalski, D. Saenko, R. Sardinov, S. Lee, S. Kim, Y. Bae, S. Lee, S. Lee, S. Yang, J. Lee, G. Park +23 moresemanticscholar +1 more sourceA descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population
Biologics: Targets & Therapy, 2018 Yusuf Yazici,1 Lin Xie,2 Adesuwa Ogbomo,2 Lorie A Ellis,3 Kavitha Goyal,4 Amanda Teeple,5 Ece A Mutlu,6 Ismail Simsek7 1Department of Internal Medicine, Division of Rheumatology, New York University Hospital for Joint Diseases, New York, NY, USA ...Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I +7 moredoaj P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study
Journal of Crohn's & Colitis
Superiority of CT-P13 subcutaneous (SC) infliximab formulation over placebo in maintenance therapy was demonstrated in both ulcerative colitis1 and Crohn’s disease2. LIBERTY-UC study was continued up to Week 102 as an extension phase treatment.B. Sands, S. Hanauer, J. Colombel, W. Sandborn, S. Schreiber, S. Danese, M. Kłopocka, R. Kulynych, J. Kierkus, A. Sołtysiak, P. Smolinski, M. Gonciarz, S. Sreckovic, E. Valuyskikh, M. Horyński, A. Gasbarrini, S. Lee, S. Kim, Y. Bae, S. Lee, S. Lee, J. Lee, J. M. Kim, J. Lee +23 moresemanticscholar +1 more sourceStrawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis
Advanced Science, Volume 13, Issue 20, 9 April 2026.This study reports that SBNO1 protein is upregulated in several cancer entities. SBNO1 protein interacts with the basal transcription factor TFIID via TAF4, enabling its recruitment to transcription start sites and the modulation of target gene expression.Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer, Thomas Albrecht, Alphonse Charbel, Michael T. Dill, Carsten Sticht, Carolina De La Torre, Stefan Pusch, Arianeb Mehrabi, Kai Breuhahn, Junfang Ji, Peter Schirmacher, Benjamin Goeppert, Stephanie Roessler +21 morewiley +1 more source
